Comparative Pharmacology
Head-to-head clinical analysis: CORTRIL versus FLOVENT HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTRIL versus FLOVENT HFA.
CORTRIL vs FLOVENT HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Fluticasone propionate is a synthetic corticosteroid that binds to glucocorticoid receptors, increasing the synthesis of lipocortins, which inhibit phospholipase A2, thereby reducing arachidonic acid release and decreasing prostaglandin and leukotriene production. It also suppresses inflammatory cell migration and cytokine release, leading to reduced airway inflammation and hyperreactivity.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
Adult: 88-880 mcg twice daily via oral inhalation; typical starting dose: 88 mcg twice daily for patients previously on bronchodilators alone, 220 mcg twice daily for patients on inhaled corticosteroids.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Terminal elimination half-life is approximately 7.8 hours (range 6.5-10.6 hours) after inhalation, supporting twice-daily dosing.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Primarily fecal (approximately 60-80%) after biliary elimination, with renal excretion accounting for <5% as unchanged drug and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid